GSK ROE 2010-2022 | GSK
Current and historical return on equity (ROE) values for GSK (GSK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| GSK ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2022-12-31 | $18.50B | $12.49B | 90.74% |
| 2022-09-30 | $16.61B | $10.27B | 67.51% |
| 2022-06-30 | $6.07B | $28.43B | 20.56% |
| 2022-03-31 | $6.97B | $30.37B | 23.26% |
| 2021-12-31 | $6.03B | $29.35B | 20.36% |
| 2021-09-30 | $6.00B | $29.99B | 20.73% |
| 2021-06-30 | $6.00B | $30.16B | 21.33% |
| 2021-03-31 | $6.86B | $28.97B | 25.56% |
| 2020-12-31 | $7.38B | $26.72B | 28.37% |
| 2020-09-30 | $8.12B | $26.64B | 32.21% |
| 2020-06-30 | $8.42B | $24.99B | 34.94% |
| 2020-03-31 | $6.86B | $25.74B | 36.43% |
| 2019-12-31 | $5.93B | $23.44B | 44.00% |
| 2019-09-30 | $5.56B | $22.27B | 62.85% |
| 2019-06-30 | $5.49B | $3.82B | 122.35% |
| 2019-03-31 | $4.85B | $4.39B | 106.35% |
| 2018-12-31 | $4.84B | $4.90B | 102.56% |
| 2018-09-30 | $2.83B | $4.85B | 61.39% |
| 2018-06-30 | $2.57B | $4.11B | 51.62% |
| 2018-03-31 | $1.74B | $5.00B | 32.45% |
| 2017-12-31 | $1.98B | $4.50B | 33.75% |
| 2017-09-30 | $2.97B | $6.32B | 46.38% |
| 2017-06-30 | $2.45B | $5.66B | 39.83% |
| 2017-03-31 | $2.05B | $6.93B | 32.87% |
| 2016-12-31 | $1.16B | $6.73B | 16.93% |
| 2016-09-30 | $0.30B | $5.25B | 3.50% |
| 2016-06-30 | $0.07B | $6.06B | 0.67% |
| 2016-03-31 | $0.93B | $9.37B | 6.91% |
| 2015-12-31 | $12.77B | $13.57B | 83.05% |
| 2015-09-30 | $14.87B | $14.47B | 106.07% |
| 2015-06-30 | $14.68B | $16.16B | 114.69% |
| 2015-03-31 | $15.57B | $17.30B | 133.77% |
| 2014-12-31 | $4.44B | $8.14B | 42.76% |
| 2014-09-30 | $6.81B | $9.61B | 59.68% |
| 2014-06-30 | $7.73B | $11.51B | 66.37% |
| 2014-03-31 | $8.22B | $12.30B | 71.10% |
| 2013-12-31 | $8.56B | $12.22B | 74.82% |
| 2013-09-30 | $6.01B | $10.54B | 54.31% |
| 2013-06-30 | $6.25B | $11.17B | 55.78% |
| 2013-03-31 | $6.62B | $11.84B | 57.63% |
| 2012-12-31 | $7.30B | $10.70B | 59.34% |
| 2012-09-30 | $7.90B | $11.10B | 60.00% |
| 2012-06-30 | $8.28B | $12.35B | 60.44% |
| 2012-03-31 | $8.10B | $15.04B | 56.01% |
| 2011-12-31 | $8.41B | $14.16B | 57.33% |
| 2011-09-30 | $5.32B | $13.27B | 35.72% |
| 2011-06-30 | $5.21B | $15.40B | 33.21% |
| 2011-03-31 | $2.98B | $15.83B | 19.36% |
| 2010-12-31 | $2.60B | $15.07B | 16.32% |
| 2010-09-30 | $6.44B | $16.45B | 40.10% |
| 2010-06-30 | $6.60B | $14.24B | 41.94% |
| 2010-03-31 | $9.29B | $17.84B | 61.25% |
| 2009-12-31 | $8.92B | $15.67B | 65.52% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $75.923B | $36.279B |
| GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $140.576B | 8.70 |
| Bio-Rad Laboratories (BIO.B) | United States | $13.735B | 32.61 |
| QIAGEN (QGEN) | Netherlands | $10.436B | 19.34 |
| Ginkgo Bioworks Holdings (DNA) | United States | $2.549B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.194B | 0.00 |
| Biohaven (BHVN) | United States | $0.913B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.394B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.152B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.106B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.012B | 0.00 |
